ZBH Stock Overview
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Zimmer Biomet Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$119.35 |
| 52 Week High | US$149.25 |
| 52 Week Low | US$102.00 |
| Beta | 1.02 |
| 1 Month Change | -9.57% |
| 3 Month Change | -2.90% |
| 1 Year Change | -13.79% |
| 3 Year Change | -32.63% |
| 5 Year Change | -3.99% |
| Change since IPO | 301.04% |
Recent News & Updates
Is Zimmer Biomet Holdings (NYSE:ZBH) Using Too Much Debt?
Mar 20
Zimmer Biomet Holdings (NYSE:ZBH) Will Pay A Dividend Of $0.24
Mar 02Recent updates
Is Zimmer Biomet Holdings (NYSE:ZBH) Using Too Much Debt?
Mar 20Zimmer Biomet Holdings (NYSE:ZBH) Will Pay A Dividend Of $0.24
Mar 02Zimmer Biomet Holdings' (NYSE:ZBH) Strong Earnings Are Of Good Quality
Feb 15What Does Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH) Share Price Indicate?
Feb 11Zimmer Biomet: Weight Loss Drug Concerns Are Overblown
Feb 05A Look At The Fair Value Of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)
Jan 29Zimmer Biomet: Growth Acceleration Is Likely Driven By ROSA; Initiate With 'Buy'
Jan 20Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Not Flying Under The Radar
Jan 15The Returns At Zimmer Biomet Holdings (NYSE:ZBH) Aren't Growing
Dec 31Zimmer Biomet Holdings: Visible Growth Drivers And Strong Execution
Dec 18Here's Why Zimmer Biomet Holdings (NYSE:ZBH) Can Manage Its Debt Responsibly
Dec 17Zimmer Biomet: Still Many Questions After A Solid Year So Far
Nov 26When Should You Buy Zimmer Biomet Holdings, Inc. (NYSE:ZBH)?
Nov 06Here's Why We Think Zimmer Biomet Holdings (NYSE:ZBH) Is Well Worth Watching
Oct 07Returns On Capital At Zimmer Biomet Holdings (NYSE:ZBH) Have Hit The Brakes
Sep 21Zimmer Biomet Holdings: Growth Strategies For 2023 Instill Confidence
Sep 14Calculating The Intrinsic Value Of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)
Sep 06Zimmer Biomet: Guidance Raise, Better Margins In 2024 Make It A Buy
Aug 11Is Zimmer Biomet Holdings (NYSE:ZBH) A Risky Investment?
Aug 08Should You Think About Buying Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Now?
Jul 10We Ran A Stock Scan For Earnings Growth And Zimmer Biomet Holdings (NYSE:ZBH) Passed With Ease
Jun 27Slowing Rates Of Return At Zimmer Biomet Holdings (NYSE:ZBH) Leave Little Room For Excitement
Jun 13A Look At The Fair Value Of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)
May 30Zimmer Biomet: Expect Growth Momentum To Continue
May 26Is Zimmer Biomet Holdings (NYSE:ZBH) Using Too Much Debt?
May 04At US$129, Is It Time To Put Zimmer Biomet Holdings, Inc. (NYSE:ZBH) On Your Watch List?
Apr 02Return Trends At Zimmer Biomet Holdings (NYSE:ZBH) Aren't Appealing
Mar 13A Look At The Intrinsic Value Of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)
Feb 21Improving Ortho Performance At Zimmer Biomet Is Encouraging
Feb 09Zimmer Biomet Q4 2022 Earnings Preview
Feb 02We Think Zimmer Biomet Holdings (NYSE:ZBH) Can Stay On Top Of Its Debt
Jan 19Zimmer Biomet to acquire soft tissue healing company Embody
Jan 05Zimmer Biomet declares $0.24 dividend
Dec 15Should You Think About Buying Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Now?
Dec 03Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Could Be 26% Below Their Intrinsic Value Estimate
Nov 17Zimmer Biomet reports Q3 earnings beat; raises FY22 guidance range
Nov 02Slowing Rates Of Return At Zimmer Biomet Holdings (NYSE:ZBH) Leave Little Room For Excitement
Oct 24Is Zimmer Biomet Holdings (NYSE:ZBH) A Risky Investment?
Oct 10Zimmer's shoulder replacement system Identity gets FDA clearance
Sep 20Zimmer Biomet Is Likely Set For Even More Weakness (Technical Analysis)
Sep 14Zimmer Biomet Holdings (NYSE:ZBH) Is Due To Pay A Dividend Of $0.24
Sep 12Zimmer, Surgical Planning team up to sell mixed reality navigation system HipInsight
Sep 01Zimmer Biomet Holdings (NYSE:ZBH) Will Pay A Dividend Of $0.24
Aug 29Zimmer Biomet declares $0.24 dividend
Aug 26Zimmer Biomet: Slow Growing Market Leader
Aug 20Are Investors Undervaluing Zimmer Biomet Holdings, Inc. (NYSE:ZBH) By 43%?
Aug 04Shareholder Returns
| ZBH | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -0.07% | 2.1% | 2.9% |
| 1Y | -13.8% | -1.9% | 22.2% |
Return vs Industry: ZBH underperformed the US Medical Equipment industry which returned -1.9% over the past year.
Return vs Market: ZBH underperformed the US Market which returned 22.2% over the past year.
Price Volatility
| ZBH volatility | |
|---|---|
| ZBH Average Weekly Movement | 3.0% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ZBH has not had significant price volatility in the past 3 months.
Volatility Over Time: ZBH's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1927 | 18,000 | Ivan Tornos | www.zimmerbiomet.com |
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products.
Zimmer Biomet Holdings, Inc. Fundamentals Summary
| ZBH fundamental statistics | |
|---|---|
| Market cap | US$24.52b |
| Earnings (TTM) | US$1.02b |
| Revenue (TTM) | US$7.39b |
23.9x
P/E Ratio3.3x
P/S RatioIs ZBH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZBH income statement (TTM) | |
|---|---|
| Revenue | US$7.39b |
| Cost of Revenue | US$2.08b |
| Gross Profit | US$5.31b |
| Other Expenses | US$4.29b |
| Earnings | US$1.02b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | 4.98 |
| Gross Margin | 71.82% |
| Net Profit Margin | 13.85% |
| Debt/Equity Ratio | 47.9% |
How did ZBH perform over the long term?
See historical performance and comparison